These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38007617)

  • 1. Non-traditional approaches for control of antibiotic resistance.
    Umarje SC; Banerjee SK
    Expert Opin Biol Ther; 2023; 23(11):1113-1135. PubMed ID: 38007617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal.
    Tarín-Pelló A; Suay-García B; Pérez-Gracia MT
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1095-1108. PubMed ID: 35576494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of vaccines on antimicrobial resistance.
    Buchy P; Ascioglu S; Buisson Y; Datta S; Nissen M; Tambyah PA; Vong S
    Int J Infect Dis; 2020 Jan; 90():188-196. PubMed ID: 31622674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial innovation: a current update and perspective on the antibiotic drug development pipeline.
    Stephens LJ; Werrett MV; Sedgwick AC; Bull SD; Andrews PC
    Future Med Chem; 2020 Nov; 12(22):2035-2065. PubMed ID: 33169622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial resistance and the post antibiotic era: better late than never effort.
    Chandra P; Mk U; Ke V; Mukhopadhyay C; U DA; M SR; V R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1375-1390. PubMed ID: 33999733
    [No Abstract]   [Full Text] [Related]  

  • 6. Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights.
    Rello J; Parisella FR; Perez A
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):635-642. PubMed ID: 31092053
    [No Abstract]   [Full Text] [Related]  

  • 7. The potential of 4D's approach in curbing antimicrobial resistance among bacterial pathogens.
    Thakur L; Singh S; Singh R; Kumar A; Angrup A; Kumar N
    Expert Rev Anti Infect Ther; 2022 Nov; 20(11):1401-1412. PubMed ID: 36098225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three Innovations of Next-Generation Antibiotics: Evolvability, Specificity, and Non-Immunogenicity.
    Shim H
    Antibiotics (Basel); 2023 Jan; 12(2):. PubMed ID: 36830114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction.
    Coates ARM; Hu Y; Holt J; Yeh P
    Expert Rev Anti Infect Ther; 2020 Jan; 18(1):5-15. PubMed ID: 31847614
    [No Abstract]   [Full Text] [Related]  

  • 10. Developments with investigating descriptors for antimicrobial AApeptides and their derivatives.
    Bolarinwa O; Cai J
    Expert Opin Drug Discov; 2018 Aug; 13(8):727-739. PubMed ID: 29933702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
    Finch R; Hunter PA
    J Antimicrob Chemother; 2006 Sep; 58 Suppl 1():i3-i22. PubMed ID: 17003063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolutionary Approaches to Combat Antibiotic Resistance: Opportunities and Challenges for Precision Medicine.
    Merker M; Tueffers L; Vallier M; Groth EE; Sonnenkalb L; Unterweger D; Baines JF; Niemann S; Schulenburg H
    Front Immunol; 2020; 11():1938. PubMed ID: 32983122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technologies to address antimicrobial resistance.
    Baker SJ; Payne DJ; Rappuoli R; De Gregorio E
    Proc Natl Acad Sci U S A; 2018 Dec; 115(51):12887-12895. PubMed ID: 30559181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Counteracting antibiotic resistance: breaking barriers among antibacterial strategies.
    Baquero F; Coque TM; Cantón R
    Expert Opin Ther Targets; 2014 Aug; 18(8):851-61. PubMed ID: 24881465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert opinion on antimicrobial therapies: is there enough scientific evidence to state that targeted therapies outperform non-targeted ones?
    Yus C; Gámez E; Arruebo M
    Expert Opin Drug Deliv; 2024 Apr; 21(4):593-609. PubMed ID: 38619078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The global preclinical antibacterial pipeline.
    Theuretzbacher U; Outterson K; Engel A; Karlén A
    Nat Rev Microbiol; 2020 May; 18(5):275-285. PubMed ID: 31745331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial Resistance (AMR).
    Tang KWK; Millar BC; Moore JE
    Br J Biomed Sci; 2023; 80():11387. PubMed ID: 37448857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution.
    Piddock LJV; Paccaud JP; O'Brien S; Childs M; Malpani R; Balasegaram M
    Clin Infect Dis; 2022 May; 74(10):1866-1871. PubMed ID: 34618892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of vaccines in fighting antimicrobial resistance (AMR).
    Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2018; 14(9):2142-2149. PubMed ID: 29787323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial resistance landscape and COVID-19 impact in Egypt, Iraq, Jordan, and Lebanon: A survey-based study and expert opinion.
    Bizri AR; El-Fattah AA; Bazaraa HM; Al Ramahi JW; Matar M; Ali RAN; El Masry R; Moussa J; Abbas AJA; Aziz MA
    PLoS One; 2023; 18(7):e0288550. PubMed ID: 37498951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.